Avian Flu: A Global Threat

Since 2022, a specific version of avian flu called H5N1 (clade 2.3.4.4b) has been killing large numbers of wild birds, poultry, and even some mammals. As it is jumping from species to species, scientists are worried it could eventually trigger a pandemic in humans. Researchers at the Icahn School of Medicine at Mount Sinai, led by Florian Krammer, PhD, wanted to see if they could create a defense against H5N1.

In their study, published in the journal Nature Communications, the team used specialized mice that are genetically designed to produce human antibodies rather than mouse ones. They then vaccinated these mice with pieces of the 2022 bird flu virus, successfully generating 16 different human antibodies that recognize the hemagglutinin (HA), also known as the the key the virus uses to break into cells.

What Makes These Antibodies Special

Most of these antibodies didn't just recognize one version of the virus; they could "see" and attack several different variants of the H5 flu family, providing broad protection. Furthermore, 14 of the 16 antibodies were able to effectively “freeze" the virus in lab tests, preventing it from infecting cells. This means the antibodies worked both as a preventative (given before infection) and as a treatment (given after infection), significantly increasing survival rates in the mice.

How They Work

Using high-tech imaging (cryo-electron microscopy), the team looked at the virus at an atomic level. They discovered that the best antibodies attach themselves to a specific, hidden groove on the head of the virus. Because this groove doesn't change much, even when the virus mutates, the antibodies remain effective.

Just as monoclonal antibodies were used to treat people during the COVID-19 pandemic, these new H5N1 antibodies could be mass-produced and used as a life-saving treatment if avian flu begins to spread rapidly among humans.